

Monthly Communicable Disease Report Summit County November, 2024



Communicable Disease Investigations (Minus Tuberculosis)

- 116 communicable disease investigations were completed.
 - Note: After an investigation has been completed, some reported cases are determined to not be a case. Therefore, the number of cases investigated may not equal the number of reportable conditions in the table below.
 - Disease investigations included: 22 cases of Hepatitis B Chronic, 15 cases of Lyme, 9 cases of Salmonella, 6 cases of Varicella, 5 cases of Campylobacter, 4 cases of CPO-Acinetobacter, 4 cases of E. Coli, 4 cases of Giardiasis, 3 cases each of the following: C. Auris, C. Auris Colonization Screening, CPO-Enterobacter, CPO-Pseudomonas, Legionella, Meningitis-Aseptic, Shigellosis and Strep pneumo. 2 cases each of the following: Amebiasis, CP-CRE, CPO- Acinetobacter Colonization Screening, Cryptosporidiosis, Haemophilus influenzae, Hepatits B- acute, Hepatitis C acute, Influenza Associated Hospitalization and Pertussis. 1 case each of the following: Hemolytic Uremic Syndrome, Hepatitis A, Meningitis Bacterial, Strep Group A and Vibriosis.

<u>Tuberculosis</u>

- 1 new confirmed cases of TB reported.
- 3 cases are being provided Direct Observed Therapy.
- 3 total TB cases currently being followed.
- Contact tracing of these new TB cases yielded 8 new contacts.

Outbreaks

- 10 New Outbreaks were identified.
 - The cause of these outbreaks included: 1 Legionella, 1 Lice, 2 Pneumonia, 4 Suspect/Confirmed Noro, 1 Hand, Foot and Mouth, and 1 E. coli, Shiga Toxin- Producing O157:H7
 - The location type of outbreaks include: Long Term Care, Therapy Center, Preschool, School, Childcare, Place of Worship
 - 16 open COVID outbreaks continue to be investigated (6 new outbreaks reported in November).

Epicenter

- Epicenter is an electronic surveillance system which provides instant notification of unusual symptomatic activity at local emergency departments.
- 11 Epicenter alerts were issued this month
 - Reasons for these alerts included: Congestion (3), Exacerbation (2), Paralysis (2), Rash (2), Diarrhea (1), Eyes (1).

Influenza Surveillance

Surveillance for the 2024-2025 flu season has begun and the first report will be issued by the end of October. Reports from previous influenza seasons are available on the SCPH website: https://www.scph.org/flu-surveillance-reports

Vector-borne Surveillance

Vector borne surveillance resumed for the season on May 19, 2024 the final report was issued at the end of October. Copies of the reports for 2024 and previous years may be accessed at: https://www.scph.org/vector-surveillance-reports

| Communicable Disease Reports Rec | Communicable Disease Reports Received, November 2024 | | | | | |
|--|--|-----------------|-----------------------|-----------------------|--|--|
| Reportable Condition | November 2024 | October 2024 | Year-to- Date 2024 | Year-to- Date 2023 | | |
| Amebiasis | 2024 | 1 | Date 2024 23 | 12 | | |
| Anaplasmosis- Anaplasma phagocytophilum | 0 | 1 | 3 | 2 | | |
| Babesiosis | 0 | 0 | 2 | 2 | | |
| Botulism - infant | 0 | 0 | 1 | 0 | | |
| Botulism, food borne | 0 | 0 | 0 | 0 | | |
| Brucellosis | 0 | 1 | 1 | 2 | | |
| C. auris | 1 | 3 | 22 | 4 | | |
| C. auris - Colonization Screening | 5 | 8 | 56 | 21 | | |
| Campylobacterosis | 5 | 10 | 89 | 94 | | |
| Chikungunya virus | 0 | 0 | 1 | 0 | | |
| Chlamydia infection | 173 | 227 | 2,426 | 2,596 | | |
| Cholera | 0 | 0 | 0 | 0 | | |
| Coccidioidomycosis | 0 | 0 | 3 | 4 | | |
| COVID-19 | 388 | 568 | 8,178 | 11,565 | | |
| CPO | 10 | 3 | 92 | 110 | | |
| CPO - Colonization Screening | 2 | 2 | 16 | 35 | | |
| Creutzfeld-Jakob Disease | 0 | 0 | 0 | 2 | | |
| Cryptosporidiosis | 2 | 2 | 21 | 16 | | |
| Cyclosporiaisis | 0 | 0 | 2 | 3 | | |
| Dengue | 0 | 0 | 0 | 1 | | |
| Diphtheria | 0 | 0 | 0 | 0 | | |
| <i>E. coli</i> , Shiga Toxin-Producing (O157:H7, Not O157, Unknown Serotype) | 4 | 5 | 34 | 17 | | |
| Ehrlichiosis- Ehrlichia chaffeensis | 0 | 0 | 1 | 2 | | |
| Giardiasis | 6 | 11 | 108 | 92 | | |
| Gonococcal infection | 74 | 96 | 980 | 974 | | |
| Haemophilus influenzae infection | 2 | 0 | 15 | 10 | | |
| Hantavirus infection | 0 | 0 | 0 | 0 | | |
| Hemolytic uremic syndrome (HUS) | 1 | 0 | 1 | 0 | | |
| Hepatitis A | 1 | 0 | 3 | 10 | | |
| Hepatitis B - acute | 2 | 1 | 6 | 6 | | |
| Hepatitis B - chronic | 9 | 9 | 80 | 103 | | |
| Hepatitis B - perinatal (see Notes on page 3) | 1 | 0 | 3 | 7 | | |
| Hepatitis C - perinatal infection | 0 | 0 | 5 | 2 | | |
| Hepatitis C- acute | 0 | 1 | 6 | 0 | | |
| Hepatitis C- chronic | 31 | 20 | 255 | 290 | | |
| Hepatitis E | 0 | 0 | 0 | 1 | | |
| HV/AIDS | 2 | 5 | 54 | 39 | | |
| Influenza - ODH Lab Results | 4 | 1 | 47 | 27 | | |
| Influenza-associated hospitalization | 8 | 1 | 323 | 58 | | |
| Influenza-associated pediatric mortality | 0 | 0 | 0 | 0 | | |
| LaCrosse virus disease | 0 | 0 | 0 | 0 | | |
| Legionellosis | 3 | 4 | 60 | 34 | | |
| Listeriosis | 0 | 0 | 1 | 1 | | |
| | | - | _ | - | | |

| Communicable Disease Reports Received, November 2024 | | | | | | |
|---|------------------|-----------------|-----------------------|-----------------------|--|--|
| Reportable Condition | November 2024 | October 2024 | Year-to- Date 2024 | Year-to- Date 2023 | | |
| Lyme Disease | 13 | 14 | 153 | 165 | | |
| MIS-C associated with COVID-19 | 0 | 0 | 0 | 0 | | |
| Malaria | 0 | 0 | 2 | 6 | | |
| MERS | 0 | 0 | 0 | 0 | | |
| Measles | 0 | 0 | 0 | 1 | | |
| Meningitis - aseptic/viral | 2 | 2 | 7 | 7 | | |
| Meningitis-bacterial (Not N. meningitidis) | 2 | 1 | 4 | 2 | | |
| Meningococcal disease-Neiserria meningitidis | 0 | 0 | 1 | 0 | | |
| Mpox (confirmed and probable) | 0 | 0 | 6 | 0 | | |
| Mumps | 0 | 0 | 0 | 0 | | |
| Pertussis | 2 | 2 | 17 | 8 | | |
| Powassan virus disease | 0 | 0 | 0 | 0 | | |
| Psittacosis | 0 | 0 | 0 | 0 | | |
| Q Fever | 0 | 0 | 3 | 0 | | |
| Rubella | 0 | 0 | 0 | 0 | | |
| Salmonella Paratyphi infection | 0 | 0 | 0 | 0 | | |
| Salmonella typhi | 0 | 0 | 0 | 0 | | |
| Salmonellosis | 9 | 12 | 92 | 63 | | |
| Shigellosis | 3 | 2 | 18 | 9 | | |
| Spotted fever rickettsiosis, including RMSF | 0 | 0 | 0 | 2 | | |
| Staphylococcal aureus - intermediate resistance to vancomycin | Ū | Ū | Ū | - | | |
| (VISA) | 0 | 0 | 1 | 0 | | |
| Streptococcal - Group A invasive | 1 | 0 | 19 | 46 | | |
| Streptococcal - Group B in newborn | 0 | 0 | 1 | 2 | | |
| Streptococcal toxic shock syndrome (STSS) | 0 | 0 | 0 | 0 | | |
| Streptococcus pneumoniae - invasive - unknown resistance | 3 | 2 | 30 | 25 | | |
| Streptococcus pneumoniae - invasive - resistant | 0 | 2 | 14 | 12 | | |
| Syphilis - all stages | | | | 292 | | |
| | 18 | 25 | 278 | | | |
| Syphilis - Congenital | 0 | 3 | 4 | 0 | | |
| Tetanus | 0 | 0 | 0 | 1 | | |
| Toxic Shock Syndrome (TSS) | 0 | 0 | 0 | 0 | | |
| Trichinellosis | 0 | 0 | 0 | 0 | | |
| Tuberculosis | 1 | 0 | 5 | 14 | | |
| Tularemia | 0 | 0 | 0 | 0 | | |
| Typhoid fever | 0 | 0 | 0 | 0 | | |
| Varicella | 3 | 2 | 0 | 5 | | |
| Vibriosis (not cholera) | 1 | 0 | 7 | 6 | | |
| West Nile virus infection | 0 | 0 | 1 | 1 | | |
| Yersiniosis | 0 | 0 | 9 | 5 | | |
| Zika virus infection | 0 | 0 | 0 | 0 | | |
| Total | 794 | 1,047 | 13,590 | 16,814 | | |

Notes:

 This report includes the number of reports of disease received and investigated by Summit County Public Health (SCPH). This includes all reports that were determined to be probable, suspected, or confirmed. Based on case investigation, clinical diagnoses, IDCM case definitions, and lab results, the case status may change. NR = not reported in previous year.

2) The Total Year-to-Date column reflects all cases of disease where SCPH is identified as the local health department in the Ohio Disease Reporting System (ODRS) as of the date that data was extracted. This includes the cases of disease entered into ODRS after last month's report was generated which will now be included in the Previous Month Revised column. Data may also vary in response to recent changes in data extraction and analysis. Because case classifications can change over time, monthly figures should not be considered final until the annual report is complete.

3) The number of perinatal hepatitis B cases reflect the number of infants born to hepatitis B positive mothers during the reporting period. These infants will be followed until serology indicates that the child has immunity. "

Epicenter figures should not be compared to previous year's reports.

For questions or comments about this report, please contact the Communicable Disease Unit at (330) 375-2662. This report was issued on December 5, 2024.